Short-course treatment with gefitinib enhances curative potential of radiation therapy in a mouse model of human non-small cell lung cancer

International Journal of Radiation Oncology Biology Physics

Volumn 88, Issue 4, 2014, Pages 947-954

  Bokobza, Sivan M ^a   Jiang, Yanyan ^a   Weber, Anika M ^a   Devery, Aoife M ^a   Ryan, Anderson J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; BIOLOGICAL ORGANS; CELL CULTURE; CELL DEATH; DAMAGE DETECTION; DISEASES; RADIATION; SIGNAL TRANSDUCTION; TUMORS;

CLONOGENIC SURVIVAL ASSAYS; EPIDERMAL GROWTH FACTOR RECEPTORS; METHODS AND MATERIALS; NON SMALL CELL LUNG CANCER; POLY(ADP-RIBOSE) POLYMERASE; RADIATION TREATMENTS; SYNERGISTIC INTERACTION; TYROSINE KINASE INHIBITOR;

RADIOTHERAPY;

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; HISTONE H2AX; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CELL KILLING; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DNA DAMAGE; DRUG SENSITIVITY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIVITY; SHORT COURSE THERAPY; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; GENES, ERBB-1; HETEROGRAFTS; HISTONES; HUMANS; LUNG NEOPLASMS; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84895740226     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2013.12.038     Document Type: Article

References (32)

1. A. Jemal, F. Bray, and M.M. Center et al. Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. S. Sun, J.H. Schiller, and A.F. Gazdar Lung cancer in never smokers - a different disease Nat Rev Cancer 7 2007 778 790
3. T.J. Lynch, D.W. Bell, and R. Sordella et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
4. W. Pao, V. Miller, and M. Zakowski et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Natl Acad Sci U S A 101 2004 13306 13311
5. J.G. Paez, P.A. Janne, and J.C. Lee et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
6. J.Y. Chang, Y.H. Liu, and Z. Zhu et al. Stereotactic ablative radiotherapy: A potentially curable approach to early stage multiple primary lung cancer Cancer 119 2013 3402 3410
7. R.D. Timmerman, and H.C. Fernando A radiation oncologist's and thoracic surgeon's view on the role of stereotactic ablative radiotherapy for operable lung cancer Semin Thorac Cardiovasc Surg 25 2013 8 13
8. P. Jain, A. Baker, and G. Distefano et al. Stereotactic ablative radiotherapy in the UK: Current status and developments Br J Radiol 86 2013 20130331
9. M. Dahele, and S. Senan The role of stereotactic ablative radiotherapy for early-stage and oligometastatic non-small cell lung cancer: Evidence for changing paradigms Cancer Res Treat 43 2011 75 82
10. J.W. Welsh, R. Komaki, and A. Amini et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer J Clin Oncol 31 2013 895 902
11. A.K. Das, B.P. Chen, and M.D. Story et al. Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma Cancer Res 67 2007 5267 5274
12. K. Dittmann, C. Mayer, and B. Fehrenbacher et al. Nuclear EGFR shuttling induced by ionizing radiation is regulated by phosphorylation at residue Thr654 FEBS Lett 584 2010 3878 3884
13. H.P. Rodemann, K. Dittmann, and M. Toulany Radiation-induced EGFR-signaling and control of DNA-damage repair Int J Radiat Biol 83 2007 781 791
14. J. O'Brien, I. Wilson, and T. Orton et al. Investigation of the alamar blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity Eur J Biochem 267 2000 5421 5426
15. N.A. Franken, H.M. Rodermond, and J. Stap et al. Clonogenic assay of cells in vitro Nat Protoc 1 2006 2315 2319
16. P. Workman, E.O. Aboagye, and F. Balkwill et al. Guidelines for the welfare and use of animals in cancer research Br J Cancer 102 2010 1555 1577
17. K. Dittmann, C. Mayer, and B. Fehrenbacher et al. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase J Biol Chem 280 2005 31182 31189
18. R. Sordella, D.W. Bell, and D.A. Haber et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways Science 305 2004 1163 1167
19. W.M. Bonner, C.E. Redon, and J.S. Dickey et al. GammaH2AX and cancer Nat Rev Cancer 8 2008 957 967
20. B. Mukherjee, C. Kessinger, and J. Kobayashi et al. DNA-PK phosphorylates histone H2AX during apoptotic DNA fragmentation in mammalian cells DNA Repair (Amst) 5 2006 575 590
21. W. Pao, V.A. Miller, and K.A. Politi et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLOS Med 2 2005 225 235
22. A.K. Das, M. Sato, and M.D. Story et al. Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation Cancer Res 66 2006 9601 9608
23. T. Kosaka, Y. Yatabe, and H. Endoh et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib Clin Cancer Res 12 2006 5764 5769
24. P. Chinnaiyan, S. Huang, and G. Vallabhaneni et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva) Cancer Res 65 2005 3328 3335
25. H.Q. Zhuang, J. Sun, and Z.Y. Yuan et al. Radiosensitizing effects of gefitinib at different administration times in vitro Cancer Sci 100 2009 1520 1525
26. A. Ahsan, S.M. Hiniker, and M.A. Davis et al. Role of cell cycle in epidermal growth factor receptor inhibitor-mediated radiosensitization Cancer Res 69 2009 5108 5114
27. S.Y. Park, Y.M. Kim, and H. Pyo Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated Mol Cancer 9 2010 222
28. Z. Gao, L. Zhuang, and Y. Chen [Effect and mechanism of gefitinib inhibition on non-small cell lung cancer radiosensitivity of HCC827 and H358 cell lines]. Zhongguo Fei Ai Za Zhi 15 2012 324 331
29. A. Shibata, S. Conrad, and J. Birraux et al. Factors determining DNA double-strand break repair pathway choice in G2 phase EMBO J 30 2011 1079 1092
30. C.H. Gow, C.R. Chien, and Y.L. Chang et al. Radiotherapy in lung adenocarcinoma with brain metastases: Effects of activating epidermal growth factor receptor mutations on clinical response Clin Cancer Res 14 2008 162 168
31. I. Okamoto, T. Takahashi, and H. Okamoto et al. Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor Lung Cancer 72 2011 199 204
32. C.C. Chang, K.H. Chi, and S.J. Kao et al. Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: A mono-institutional experience Lung Cancer 73 2011 189 194